A new type of vaccine that can be stored at warmer temperatures, removing the need for refrigeration, has been developed for mosquito-borne virus Chikungunya in a major advance in vaccine technology.
The findings, published in Science Advances today [Wednesday 25 September], reveal exceptionally promising results for the Chikungunya vaccine candidate, which has been engineered using a synthetic protein scaffold that could revolutionise the way vaccines are designed, produced and stored.
Infectious diseases continue to plague populations worldwide. Among the means at our disposal to counter this threat, vaccination has proven to be exceptionally powerful. Smallpox has been eradicated, measles, polio and tetanus constrained from the world by vaccination. However, severe challenges to human health persist, evidenced by epidemics caused by Ebola, Zika and others. This is particularly severe in developing countries which often lack adequate infrastructure and resources to prevent or manage outbreaks, bringing about disruption and damage in affected communities and massive economic shortfall.
A recent example is Chikungunya, a virus transmitted by the bite of an infected mosquito. The disease causes crippling headache, vomiting, swelling of limbs and can lead to death. Even if a fever ends abruptly, chronic symptoms such as intense joint pain, insomnia and extreme prostration remain. Formerly confined to sub-Saharan Africa, Chikungunya has recently spread worldwide as its mosquito host leaves its natural habitat due to deforestation and climate change, with recent outbreaks in USA and Europe causing alarm.
Researchers from the University of Bristol and the French National Centre for Scientific Research (CNRS) in Grenoble, France, teamed up with computer technology giant Oracle to find a way to make vaccines that are thermostable (able to withstand warm temperatures), can be designed quickly and are easily produced.
“We were working with a protein that forms a multimeric particle resembling a virus but is completely safe, because it has no genetic material inside, said Pascal Fender, expert virologist at CNRS. “Completely by chance, we discovered that this particle was incredibly stable even after months, without refrigeration.”
“This particle has a very flexible, exposed surface that can be easily engineered, added Imre Berger, Director of the Max Planck-Bristol Centre for Minimal Biology in Bristol. “We figured that we could insert small, harmless bits of Chikungunya to generate a virus-like mimic we could potentially use as a vaccine.”
To validate their design, the scientists employed cryo-electron microscopy, a powerful new technique recently installed in Bristol’s state-of-the-art microscopy facility headed by Christiane Schaffitzel, co-author of the study. Cryo-EM yields very large data sets from which the structure of a sample can be determined at near atomic resolution, requiring massive parallel computing.
Enabled by Oracle’s high-performance cloud infrastructure, the team developed a novel computational approach to create an accurate digital model of the synthetic vaccine. University of Bristol IT specialists Christopher Woods and Matt Williams, together with colleagues at Oracle, implemented software packages seamlessly on the cloud in this pioneering effort. Christopher explained: “We were able to process the large data sets obtained by the microscope on the cloud in a fraction of the time and at much lower cost than previously thought possible.”
“Researchers have had a long tradition of building and installing their own super computers on-premises, but cloud computing is allowing them to run large data sets in record time, with fast connectivity and low latency. This is helping them crunch data and make scientific breakthroughs much faster. Going forward, technologies like machine learning and cloud computing will play a significant part in the scientific world, and we are delighted we could help the researchers with this important discovery,” added Phil Bates, leading cloud architect at Oracle.
The particles the scientists designed yielded exceptionally promising results in animal studies, soundly setting the stage for a future vaccine to combat Chikungunya disease.
“We were thoroughly delighted,” continued Imre Berger. “Viruses are waiting to strike, and we need to have the tools ready to tackle this global threat. Our vaccine candidate is easy to manufacture, extremely stable and elicits a powerful immune response. It can be stored and transported without refrigeration to countries and patients where it is most needed. Intriguingly, we can now rapidly engineer similar vaccines to combat many other infectious diseases just as well.”
“It really ticks a lot of boxes,” concluded Fred Garzoni, founder of Imophoron Ltd, a Bristol biotech start-up developing new vaccines derived from the present work. “Many challenges in the industry require innovative solutions, to bring powerful new vaccines to patients. Matching cutting-edge synthetic biology with cloud computing turned out to be a winner.”
The Latest on: Synthetic vaccines
via Google News
The Latest on: Synthetic vaccines
- Synthetic Sapphire Market Is Poised to Expand at a Stellar 6.4% CAGR, Reaching USD 6.4 Mn by 2028 | 104 Report Pageson August 4, 2022 at 10:56 am
The increasing use of Synthetic Sapphire in Medical, Electronic Products, Aviation, Other and other industries is driving the growth of the ...
- FDA continues to sift through synthetic nicotine productson August 4, 2022 at 7:00 am
The letters to manufacturers whose applications weren’t up to snuff “state that it is illegal to sell or distribute in the U.S. marketplace any new tobacco product that has not received premarket ...
- SK Bioscience seeks approval for its SKY Covione COVID vaccine in Europeon August 3, 2022 at 4:23 am
SK Bioscience has applied for conditional approval for the use of SKY Covione, a COVID-19 vaccine, with the European Medicines Agency (EMA). SKY Covione, developed jointly by the biotech affiliate of ...
- Global Synthetic Biology Market Is Projected to Grow at a CAGR of 25.52% by 2032: Visiongain Reports Ltdon August 3, 2022 at 2:31 am
Visiongain has published a new report entitled Synthetic Biology 2022-2032. It includes profiles of Synthetic Biology and Forecasts Market Segment by Product Type (Application Product Type, Technology ...
- Emergex starts up production for universal influenza vaccineon August 1, 2022 at 2:18 am
The UK company plans to manufacture sufficient levels of its universal influenza vaccine for use in Phase I human trials.
- SK Bioscience seeks approval for COVID vaccine in Europeon August 1, 2022 at 12:43 am
By Lee Kyung-min SK Bioscience, a biotech affiliate of SK Group, said Monday that it has applied for a conditional approval for the use of SKY Covione, a COVID-19 vaccine, with th ...
- Taiwan Vaccine Adjuvant Pioneer ImmunAdd to Attend 2022 BIO International Convention in San Diegoon July 28, 2022 at 10:46 pm
ImmunAdd's next-generation Saponin-based adjuvant IA-05 induced both humoral and cellular immunities in various vaccines, including those against ...
- How can vaccines keep up with evolving Covid-19 variants?on July 28, 2022 at 2:51 am
Vaccines for Covid-19 are rolling out all over the world, but their protection is threatened by the rise of variants of concern. Companies are developing ways to combat the evolving virus, such as ...
- Emergex Announces GMP Production of its CD8+ T cell Universal Influenza Vaccineon July 27, 2022 at 11:02 pm
PRESS RELEASE Emergex Announces GMP Production of its CD8+ T cell Universal Influenza Vaccine Emergex will manufacture the candidate universal influenza vaccine to cGMP standards for use in Phase I ...
- The FDA needs to get ready to evaluate synthetic cells, the next generation of therapeuticson July 26, 2022 at 1:55 am
Long before the first synthetic cell is tested for treatment, the FDA needs to develop a regulatory framework for this new therapeutic approach. Otherwise, the future of these therapies could be ...
via Bing News